CVR number 35812482
Industry 72.1100 Research and experimental development on biotechnology

AMAGON ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Bankruptcy risk for industry  1.2% 1.2% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 29.1% 13.3% 15.6%  
Credit score (0-100)  0 0 2 19 13  
Credit rating  N/A N/A C BB BB  
Credit limit (kDKK)  0.0 0.0 -0.0 -0.0 -0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 60.1 52.3 -154  
EBITDA  0.0 0.0 -123 -85.2 -800  
EBIT  0.0 0.0 -123 -85.2 -800  
Pre-tax profit (PTP)  0.0 0.0 -122.7 -82.7 -827.3  
Net earnings  0.0 0.0 -122.5 -83.0 -827.3  
Pre-tax profit without non-rec. items  0.0 0.0 -123 -82.7 -827  
 
See the entire income statement

Balance sheet (kDKK) 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 -28.1 -111 -938  
Interest-bearing liabilities  0.0 0.0 10.0 182 181  
Balance sheet total (assets)  0.0 0.0 10.4 99.6 412  
Net Debt  0.0 0.0 -0.4 86.1 -228  
 
See the entire balance sheet

Volume 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 60.1 52.3 -154  
Gross profit growth  0.0% 0.0% 0.0% -13.0% 0.0%  
Employees  0 0 1 1 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 100.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 10 100 412  
Balance sheet change%  0.0% 0.0% 0.0% 861.0% 313.6%  
Added value  0.0 0.0 -122.6 -85.2 -800.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 -2.0 -3.0  

Profitability 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% -204.0% -163.0% 518.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -318.4% -66.3% -102.2%  
ROI %  0.0% 0.0% -1,226.2% -86.2% -112.5%  
ROE %  0.0% 0.0% -1,182.0% -151.0% -323.4%  

Solidity 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Equity ratio %  0.0% 0.0% -73.1% -52.7% -69.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% 0.3% -101.0% 28.5%  
Gearing %  0.0% 0.0% -35.5% -163.4% -19.3%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.9% 0.1% 16.1%  

Liquidity 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Quick Ratio  0.0 0.0 0.3 0.5 1.4  
Current Ratio  0.0 0.0 0.3 0.5 1.4  
Cash and cash equivalent  0.0 0.0 10.4 95.6 409.9  

Capital use efficiency 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 -28.1 -111.2 117.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2014
N/A
2015
N/A
2016
2016/12
2017
2017/12
2018
2018/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 -123 -85 -400  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 -123 -85 -400  
EBIT / employee  0 0 -123 -85 -400  
Net earnings / employee  0 0 -123 -83 -414